Advancing the Treatment of Intracranial Atherosclerotic
ICAD is the result of cholesterol plaque building up in arteries in the brain. It is a leading cause of stroke globally.
ICAD: ONE OF THE LEADING CAUSES OF ISCHEMIC STROKE WORLDWIDE
We are delighted to announce that Ceroflo is now in a position to start hiring the pivotal R&D team to fast track the development of its novel technology for the treatment of Intracranial Atherosclerotic Disease (ICAD).
We believe excellent product performance is critical to success, so recruitment of the key R&D team is our first priority. We are recruiting R&D professionals with intravascular device development experience for several key positions including:
- R&D Manager
- Senior R&D Engineer
- R&D Engineer level roles
If you have relevant experience and are interesting in joining an early-stage fast-growing start-up with a highly experienced management team, please get in touch with Ceroflo at info@Ceroflo.com